Filtered By:
Drug: Fenofibrate

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Abstract P160: Role of Uncoupling Protein 2 in Stroke Susceptibility of Stroke-prone Spontaneously Hypertensive Rat Session Title: Cerebrovascular Disease and Stroke
Mitochondrial dysfunction causes severe cellular derangements potentially underlying tissue injury and consequent diseases. Evidence of a direct involvement of mitochondrial dysfunction in hypertensive target organ damage is still poor.The gene encoding Uncoupling Protein 2 (UCP2), a inner mitochondrial membrane protein, maps inside stroke QTL/STR1 in stroke prone spontaneously hypertensive rat (SHRSP). We explored the role of UCP2 in stroke pathogenesis of SHRSP. Male SHRSP, stroke resistant SHR (SHRSR) and reciprocal STR1/congenic rats were fed with stroke permissive Japanese style diet (JD). A group of SHRSP received JD...
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Rubattu, S., Cotugno, M., Bianchi, F., Di Castro, S., Stanzione, R., Busceti, C., Marchitti, S., Nicoletti, F., Volpe, M. Tags: Session Title: Cerebrovascular Disease and Stroke Source Type: research

Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study
Conclusions Older people with a history of stroke were at highest risk of stroke, but the prognosis and prognostic factors of subtypes were heterogeneous. The results will help clinicians quantify the absolute risk of stroke and its subtypes for typical diabetes patients.
Source: Journal of Neurology, Neurosurgery and Psychiatry - February 15, 2013 Category: Neurosurgery Authors: Hankey, G. J., Anderson, N. E., Ting, R.-D., Veillard, A.-S., Romo, M., Wosik, M., Sullivan, D. R., O'Connell, R. L., Hunt, D., Keech, A. C. Tags: Stroke, Hypertension, Ophthalmology, Ischaemic heart disease Cerebrovascular disease Source Type: research

Sex differences and the role of PPAR alpha in experimental stroke
Abstract Males and females respond differently to stroke. Moreover, females often experience worse long-term stroke outcomes. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist has been shown to improve stroke outcome and resolve neuroinflammation in male mice. The present study compares the effect of pretreatment with fenofibrate versus vehicle control in male and female mice during experimental stroke. Mice were treated with low-dose fenofibrate 30 min before and once a day for three additional days after stroke onset. We observed a reduction in infarct volume in male mice 96 h p...
Source: Metabolic Brain Disease - May 11, 2016 Category: Neurology Source Type: research

Fibrates for secondary prevention of cardiovascular disease and stroke.
CONCLUSIONS: Moderate evidence showed that the fibrate class can be effective in the secondary prevention of composite outcome of non-fatal stroke, non-fatal MI, and vascular death. However, this beneficial effect relies on the inclusion of clofibrate data, a drug that was discontinued in 2002 due to its unacceptably large adverse effects. Further trials of the use of fibrates in populations with previous stroke and also against a background treatment with statins (standard of care) are required. PMID: 26497361 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - October 25, 2015 Category: Journals (General) Authors: Wang D, Liu B, Tao W, Hao Z, Liu M Tags: Cochrane Database Syst Rev Source Type: research

PPAR-Alpha Agonist Used at the Acute Phase of Experimental Ischemic Stroke Reduces Occurrence of Thrombolysis-Induced Hemorrhage in Rats.
Authors: Gautier S, Ouk T, Pétrault M, Pétrault O, Bérézowski V, Bordet R Abstract The impact of fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist, on the risk of thrombolysis-induced hemorrhage during the acute phase of stroke in a rat model of stroke was studied. One-hour middle cerebral artery occlusion followed by thrombolysis with tissue plasminogen activator was made in rats receiving either fenofibrate or vehicle for 72 h after stroke. Evaluation of infarct, hemorrhage, middle cerebral artery vasoreactivity, and immunochemistry (CD11b for microglial activation, myelopero...
Source: PPAR Research - June 26, 2015 Category: Genetics & Stem Cells Tags: PPAR Res Source Type: research

Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke
Conclusions: Pre-treatment with PPARalpha agonist or atorvastatin show potential neuroprotective effects by inhibiting the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity. This proteomic study therefore suggests that neuroprotective effect of PPARalpha agonists supposes the preservation of the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly linked to PPARalpha known-regulated targets.
Source: Proteome Science - May 6, 2014 Category: Bioinformatics Authors: Patrick GeléValérie VingtdeuxCamille PoteyHervé DrobecqAntoine GhestemPatricia MelnykLuc BuéeNicolas SergeantRégis Bordet Source Type: research

Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection
Conclusion: The results suggest that the cardiorenal protective effects of fenofibrate in young male salt-loaded SHRSPs are explained by its capacity to preserve mitochondrial function.
Source: Journal of Hypertension - March 27, 2018 Category: Cardiology Tags: ORIGINAL PAPERS: Pathophysiological aspects Source Type: research

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial.
CONCLUSIONSIn the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality. PMID: 24595629 [PubMed - as supplied by publisher]
Source: Diabetes Care - March 4, 2014 Category: Endocrinology Authors: Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Venkat Narayan KM, Riddle MC, Sood A, Goff DC Tags: Diabetes Care Source Type: research

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
CONCLUSIONS: Moderate- to high-quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non-fatal MI and non-fatal stroke, but it has little or no effect on clinical fatal endpoints. The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides. There is insufficient evidence to determine whether ezetimibe increases the risk of adverse events due to the low and very low quality of the evidence. The evidence for beneficial effects was mainly obtained from individuals with established atheroscler...
Source: Cochrane Database of Systematic Reviews - November 19, 2018 Category: General Medicine Authors: Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X Tags: Cochrane Database Syst Rev Source Type: research

Abstract 298: Fibrate use in patients with type 2 diabetes Poster Session III
In conclusion, the prevalence of atherogenic dyslipidemia among patients with type 2 diabetes has increased significantly over the past decade. However, fibrate use in all patients with type 2 diabetes, including those specifically with atherogenic dyslipidemia, has remained constant throughout the observation period, despite lack of conclusive evidence supporting its use.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: McCoy, R. G., Van Houten, H. K., Shah, N. D. Tags: Poster Session III Source Type: research

Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Conclusions/interpretation Fenofibrate improved the lipoprotein profile more in women than men. Cardiovascular event reductions with fenofibrate were consistently similar in women and men, both overall and among those with low HDL-cholesterol and high triacylglycerol levels. These data provide reassurance about fenofibrate efficacy in women and men. Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection.
Source: Diabetologia - October 1, 2014 Category: Endocrinology Source Type: research

Serum 25-Hydroxy Vitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes.
CONCLUSIONS: Low blood 25OH-D concentrations are associated with an increased risk of macrovascular and microvascular disease events in type 2 diabetes. However, a causal link remains to be demonstrated. PMID: 25524951 [PubMed - as supplied by publisher]
Source: Diabetes Care - December 18, 2014 Category: Endocrinology Authors: Herrmann M, Sullivan DR, Veillard A, McCorquodale T, Straub IR, Scott R, Laakso M, Topliss D, Jenkins AJ, Blankenberg S, Burton A, Keech AC, for the FIELD study investigators Tags: Diabetes Care Source Type: research

Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes
CONCLUSIONS Low blood 25OH-D concentrations are associated with an increased risk of macrovascular and microvascular disease events in type 2 diabetes. However, a causal link remains to be demonstrated.
Source: Diabetes Care - February 24, 2015 Category: Endocrinology Authors: Herrmann, M.; Sullivan, D. R.; Veillard, A.-S.; McCorquodale, T.; Straub, I. R.; Scott, R.; Laakso, M.; Topliss, D.; Jenkins, A. J.; Blankenberg, S.; Burton, A.; Keech, A. C.; for the FIELD Study Investigators Tags: Cardiovascular and Metabolic Risk Source Type: research

The role of PPAR activation during the systemic response to brain injury
Conclusions: The data highlight a novel mechanism of action for fenofibrate and lend further evidence towards the promotion of its use as a prophylactic therapy in patients at risk of cerebral ischaemia. Further research is required to elucidate the mechanistic explanation underlying its actions.
Source: Epidemiologic Perspectives and Innovations - May 21, 2015 Category: Epidemiology Authors: Patrick LoseyEmma LaddsMaud LapraisBorna GeuvelLaura BurnsRegis BordetDaniel C Anthony Source Type: research

Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
ConclusionsThe data may indicate that in people with Type 2 diabetes, which is associated with higher alanine aminotransferase levels because of prevalent non‐alcoholic fatty liver disease, a low alanine aminotransferase level is a marker of hepatic or systemic frailty rather than health.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - October 3, 2015 Category: Endocrinology Authors: K. H. Williams, D. R. Sullivan, A. S. Veillard, R. O'Brien, J. George, A. J. Jenkins, S. Young, C. Ehnholm, A. Duffield, S. M. Twigg, A. C. Keech Tags: Research Article Source Type: research